KAKenny Kwabena Ablordeppey

Kenny Kwabena Ablordeppey

*This is an algorithmically generated author record based on publicly available information.

Kenny Kwabena Ablordeppey has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens

    by Sophia Giliberto, Kenny K. Ablordeppey, Jacob Goldman, Melinda Yin, Rahul Chowdhury, Jacob Till, Kira Sheinerman, Sydney D. Finkelstein, Samuil Umansky, Alidad Mireskandari, et al.

    Background: Noninvasive biomarkers for the detection and monitoring of glioblastoma (GBM) are needed to improve clinical outcomes for patients. The objective of this pilot study was to evaluate the expression of a panel of 48 pre-selected microRNAs (miRNAs) in plasma specimens from GBM patients versus healthy controls to identify candidate miRNA biomarkers for noninvasive diagnosis of GBM. Methods: Selection of candidate miRNA biomarkers was based on a comprehensive literature review and data mining. RNA was extracted from plasma samples obtained prior to resection from patients with GBM (n = 30) and age- and sex-matched healthy controls (n = 30), as well as from matched FFPE GBM tissue samples when available (n = 3). Expression levels of 48 miRNAs were assessed in all samples, and expression data was processed using proprietary software to generate potential biomarkers and train linear classifiers. Results: Overall miRNA expression patterns were similar between matched plasma and FFPE tumor tissues in patients with GBM. miRNA levels were examined in pairs to determine the ratio between two miRNAs, which served to normalize the data. The top five miRNA pairs for distinguishing between GBM and healthy control plasma included miR-17-5p/miR-19b-3p (AUC 0.93, 95% CI = 0.870, 0.970), miR-20a-5p/miR-19b-3p (AUC 0.93, 95% CI = 0.870, 0.970), miR-93-5p/miR-92a-3p (AUC 0.92, 95% CI = 0.875, 0.965), miR-17-5p/miR-92a-3p (AUC 0.91, 95% CI = 0.865, 0.955), and miR-93-5p/miR-19b-3p (AUC 0.90, 95% CI = 0.850, 0.950). For the development of a multi-biomarker combination classifier consisting of up to three miRNA pair biomarkers, miRNA pairs with an AUC ≥ 0.8 were selected to build equal-weight linear classifiers. All possible combinations of three high-performing miRNA pairs were tested across the 60 samples. The top classifier (miR-20a-5p/miR-451a, miR-582-5p/miR-222-3p, and miR-17-5p/miR-222-3p) achieved an AUC value of 0.992, sensitivity of 0.93, specificity of 1, and accuracy of 0.97. Conclusions: These findings support the continued development of a plasma-based miRNA molecular diagnostic approach for the detection of GBM. The strong discriminatory performance observed in this study, including high AUC values, highlights the potential of circulating miRNA signatures as a minimally invasive diagnostic tool. As a pilot analysis, this work establishes a foundation for future prospective studies in larger, independent cohorts—including relevant disease control populations—to further define clinical performance, specificity, and utility in diagnostic and monitoring settings. Collectively, these results represent an important step toward the translation of plasma-based miRNA profiling into clinical application for GBM.


  • Open Access

    Circulating brain‐enriched microRNAs as peripheral biomarkers of neurodegeneration

    by Alidad Mireskandari, Gyanendra Kumar, Arzu Kunwar, Kenny K Ablordeppey, Michael Kiefer, David A. Wolk, Kira S. Sheinerman, Samuil R. Umansky

    Background: Minimally invasive diagnostic tools are needed to better characterize heterogeneous groups of patients with mild cognitive impairment (MCI), pre‐MCI, and dementia. At DiamiR, we developed an approach based on targeted selection and quantitative analysis of microRNAs enriched in specific brain regions, present in synapses, and detectable in blood plasma. microRNAs are short, non‐coding regulatory molecules whose levels change in disease.Method: Concentrations of 24 brain‐enriched and inflammation‐associated microRNAs (Table 1) were analyzed in plasma samples of 200 study participants with the following clinical diagnoses at the time of blood draw: 76 cognitively unimpaired (CU), 85 MCI, and 39 Alzheimer’s disease (AD). The demographic characteristics and clinical data of the study participants are summarized in Table 2. The plasma samples were collected at the Penn Alzheimer’s Disease Research Center (ADRC). Based on amyloid status (Abeta+/‐), APOE genotype (APOE4 +/‐), and sex, each sample was assigned to a specific subgroup. RNA from plasma samples was isolated using the MagMAX mirVana kit (ThermoFisher). microRNA concentrations were measured by qPCR using custom plates (Qiagen) pre‐plated with lyophilized miRCURY LNA‐based primers for a 24‐microRNA panel. Differentiation of subgroups by microRNA pairs and their combinations (classifiers) was evaluated using a proprietary software program developed at DiamiR.Result: Using the ratio between two microRNAs as a biomarker (“pair” approach) reduces variability and enhances specificity and sensitivity. Effective microRNA pairs were combined into classifiers. Data on the differentiation of subgroups using one, two, and three microRNA pairs are presented in Table 3.In line with our prior results, sex‐stratified analysis yielded higher AUC values for females and males as compared to the combined group. Interestingly, microRNAs differ in effective pairs for female and male subgroups. For example, levels of inflammation‐associated miR‐146a were higher in female MCI/AD study participants. However, sex‐stratified groups were relatively small and further assessment is required.Conclusion: These data support the development of assays based on the analysis of circulating brain‐enriched and inflammation‐associated microRNAs for better characterization of MCI/AD patients and understanding of AD‐associated processes. Further, combining these microRNAs with other factors, such as amyloid and APOE, may enhance a biomarker algorithm.

  • Open Access

    Analytical Validation of Novel microRNA Panel for Risk Stratification of Cognitive Impairment

    by Arzu Kunwar, Kenny K Ablordeppey, Alidad Mireskandari, Kira S. Sheinerman, Michael Kiefer, Samuil R. Umansky, Gyanendra Kumar

    Background: We have been developing a novel approach to identify risk of early cognitive impairment in patients by profiling of brain‐enriched and inflammation‐associated microRNA (miRNA) biomarkers, isolated from the plasma of cognitively normal and cognitively impaired patients. Here, we present the analytical validation of a miRNA panel, (CogniMIR®), for the expression of 24 miRNAs for large‐scale testing of plasma specimens in a clinical laboratoryMethod: miRNA from plasma specimens was isolated using the MagMAX mirVana kit (ThermoFIsher). 24 synthetic miRNAs oligos (IDT) werecombined and diluted to create quantification markers for making standard curves. RT was performed using miRCURY LNA RT kit. qPCR for miRNA profiling was carried out using custom plates (Qiagen), pre‐plated with lyophilized miRCURY LNA‐based primers for 24 miRNAs of the (CogniMIR®) panel. qPCR was perfomred on a Quantstudio 7 Flex instrument.Result: Synthetic RNA dilution series for 24 miRNAs (200,000 copies, 20000 copies, 2000 copies, 200 copies and 20 copies in a qPCR reaction) were tested on two different days. Average slope of the standard curves for all 24 miRNAs were determined to be in ‐3.3 to ‐3.7 range, and average R2 was 0.99 to 1. The data demonstrates that all 24 synthetic miRNAs of the (CogniMIR®) panel can be reliably and consistently detected even if the sample input is 20 copies in a qPCR reaction.Intra‐run repeatability analysis, using plasma samples from four subjects was tested by two operators on two different days. The data demonstrated that both operators generated repeatable and consistent Cts in both replicates on both days as seen by R2 value of 0.94 to 0.99. The inter‐run data analysis, using the same four samples tested by two operators on two different days, showed that reproducible Ct data were obtained by both operators when the experiment was repeated on the next day as demonstrated by R2 value of 0.96 to 0.97.Conclusion: These results indicate the utility of the (CogniMIR®) panel for miRNA profiling, and demonstrate that our miRNA detection technology is reliable, reproducible, and operationally friendly to test a large scale of specimens in any CAP/CLIA certified clinical laboratory.


  • Open Access

    Analytical Validation of a Novel MicroRNA Panel for Risk Stratification of Cognitive Impairment

    by Arzu Kunwar, Kenny Kwabena Ablordeppey, Alidad Mireskandari, Kira Sheinerman, Michael Kiefer, Samuil Umansky, Gyanendra Kumar

    We have been developing a novel approach to identify cognitive impairment-related biomarkers by profiling brain-enriched and inflammation-associated microRNA (miRNA) in plasma specimens of cognitively unimpaired and cognitively impaired patients. Here, we present an analytical validation of the novel miRNA panel, CogniMIR®, using two competing quantitative PCR technologies for the expression analysis of 24 target miRNAs. Total RNA from the plasma specimens was isolated using the MagMAX mirVana Kit, and RT-qPCR was performed using stem-loop-based TaqMan and LNA-based qPCR assays. Evaluation of RNA dilution series for our target 24 miRNAs, performed by two operators on two different days, demonstrated that all CogniMIR® panel miRNAs can be reliably and consistently detected by both qPCR technologies, with sample input as low as 20 copies in a qPCR reaction. Intra-run and inter-run repeatability and reproducibility analyses using RNA specimens demonstrated that both operators generated repeatable and consistent Cts, with R2 values of 0.94 to 0.99 and 0.96 to 0.97, respectively. The study results clearly indicate the suitability of miRNA profiling of plasma specimens using either of the qPCR technologies. However, the LNA-based qPCR technology appears to be more operationally friendly and better suited for a CAP/CLIA-certified clinical laboratory.


  • Open Access

    Development and Analytical Validation of an Expanded Mutation Detection Panel for Next-Generation Sequencing of Thyroid Nodule Aspirates

    by Kenny K. Ablordeppey, Venkata A. Timmaraju, Joanna W. Song-Yang, Sharon Yaqoob, Christina Narick, Alidad Mireskandari, Sydney D. Finkelstein, Gyanendra Kumar